Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Product |
Terms/Details (Date) |
Aero Pharmaceuticals Inc.* |
Akorn Inc. |
Akorn will provide contract manufacturing services for Aero |
Details on the terms and products were not disclosed (5/6) |
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
Gerolymatos Group of Companies (Greece) |
Gerolymatos got exclusive rights to Avanir's docosanol 10% cream in Greece, Cyprus, Turkey and Romania |
Avanir will receive a data-transfer fee, a potential milestone payment and royalties on any sales of the product, which is sold in the U.S. as Abreva for cold sores (6/14) |
Carrington Laboratories Inc. (CARN) |
Medline Industries Inc. |
Extension of deal under which Medline will sell Carrington's wound and skin-care products |
The deal, set to expire in November 2005, was extended through November 2008; Carrington gets a $1.25M royalty paymentand will continue manufacturing products (4/22) |
Corixa Corp. (CRXA) |
Australian Nuclear Science and Technology Organization (Australia) |
ANSTO got exclusive rights to develop and sell Bexxar in much of the Australia-Asia region and coexclusive rights in Japan, South Korea and Taiwan |
Under the 12-year deal, ANSTO will pay Corixa an up-front licensing fee and regulatory milestone payments, as well as payments based on sales volume and royalties on sales (5/19) |
Genmab A/S |
DSM Biologics |
DSM will produce a commercial supply of HuMax-CD4 |
DSM will manufacture Genmab's antibody (Denmark; CSE:GEN) for T-cell lymphoma, both for clinical trials and subsequent commercialization (6/1) |
Guilford Pharmaceuticals Inc. (GLFD) |
Link Pharmaceuticals Ltd. (UK) |
Link will distribute the Gliadel Wafer in Germany, Switzerland, France, Benelux and Austria |
Link already sells the product for brain cancer in the UK; Guilford got $500,000 up front and could get up to $2M in milestone payments; Link is responsible for getting approvals in the covered countries (5/17) |
Isotechnika Inc. (Canada; TSE: ISA) |
Lonza Group Ltd. (Switzerland) |
Lonza will manufacture Isotechnika's trans-ISA247 for upcoming clinical trials |
The companies formalized a manufacturing deal; terms were not disclosed (6/8) |
Matritech Inc. (AMEX:MZT) |
Inverness Medical Innovations Inc. |
Deal for the distribution of Matritech's NMP22 Test Kit for cancer detection |
Inverness subsidiary Wampole Laboratories LLC got exclusive rights to sell to hospitals and laboratories in the U.S. (6/7) |
MedImmune Inc. (MEDI) |
Henry Schein Inc. |
Henry Schein was named exclusive U.S. distributor of FluMist for the upcoming flu season |
MedImmune will oversee all sales and mar- keting activities for FluMist, whose price was cut in half to $23.50 per dose; terms were not disclosed (6/15) |
Pharmion Corp. (PHRM) |
Ash Stevens Inc. |
Ash Stevens got FDA approval to manufacture 5-azacitidine for Pharmion's Vidaza |
Vidaza was approved May 20 for the treat- ment of myelodysplastic syndromes (5/21) |
Pierce Biotechnology Inc.* |
Tecan Group Ltd. (Switzerland) |
Agreement to develop and co- market high-throughput screening solutions with fluorescence lifetime technology |
They will combine technologies in the effort, and share product information and support; terms were not disclosed (5/17) |
RheoGene Inc.* |
New England Biolabs |
NEB licensed rights to RheoGene's RheoSwitch inducible gene regulation technology |
NEB can develop and distribute research kits and related products based on the technology, and got nonexclusive rights to develop combination research products that incorporate the technology (6/8) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; TSE = Toronto Stock Exchange. | |||
